Processa Pharmaceuticals (PCSA) has released an update.
Processa Pharmaceuticals, Inc. announced the successful completion of a Phase 1b safety evaluation for NGC-Cap in patients with advanced cancer, identifying recommended doses for Phase 2 trials.
For further insights into PCSA stock, check out TipRanks’ Stock Analysis page.
